# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>A Letter From Our President</td>
<td>02</td>
</tr>
<tr>
<td>A Letter From Our Executive Director</td>
<td>03</td>
</tr>
<tr>
<td>A Report From Our Research Committee Chair</td>
<td>04</td>
</tr>
<tr>
<td>2020-2021 Research Funding</td>
<td>06</td>
</tr>
<tr>
<td>Clinical Trial Updates</td>
<td>09</td>
</tr>
<tr>
<td>ICRN</td>
<td>10</td>
</tr>
<tr>
<td>International Advocacy Efforts</td>
<td>13</td>
</tr>
<tr>
<td>Patient and Family Services</td>
<td>15</td>
</tr>
<tr>
<td>CHM Family Accomplishments</td>
<td>16</td>
</tr>
<tr>
<td>Financial Summary</td>
<td>19</td>
</tr>
<tr>
<td>Board of Directors</td>
<td>20</td>
</tr>
<tr>
<td>Officers at Large</td>
<td>20</td>
</tr>
<tr>
<td>Directors</td>
<td>21</td>
</tr>
<tr>
<td>Scientific Advisory Board</td>
<td>22</td>
</tr>
<tr>
<td>Staff</td>
<td>24</td>
</tr>
<tr>
<td>Donors</td>
<td>25</td>
</tr>
</tbody>
</table>
Hello to our global CRF Members, CHMers, their families, and our research community,

The Chroideremia Research Foundation continues to set its sights towards expanded research, patient support and an enjoyable CRF 2022 Conference June 15-18 in Rochester, NY. We have numerous excellent speakers lined up and many people are looking forward to seeing each other in person again. We continue to look forward, work for advancements, and improve the lives of all that touch the CRF.

As you can see from the research update, we are advancing in several areas including the creation of a large animal CHM model. We have heard from several researchers and institutions that the availability of a large animal model would be useful in many ways. Also, Kathi Wagner, Executive Director, will provide an update on our International Chroideremia Research Network that was started in 2021, as an effort to encourage interaction and collaboration opportunities within the research community. I would also like to highlight a generous donation received in 2021 to initiate our first research endowment fund. This is an outstanding start towards the development of an asset to help fund early career CHM researchers.

Thank you to everyone who has generously donated in support of the CRF and its research and program efforts. Our many board and committee members as well as volunteers continue to help move the CRF to the forefront. Also, much appreciation to our staff that helps us head in the right direction and communicate with our members, supporters, researchers and partners throughout the world.

Best Regards,

Neal Bench, President
2021 was a year of highs and lows for CRF and the CHM community.

First the lows. Unfortunately, two of the three clinical trials underway for choroideremia were officially discontinued. In no uncertain terms, this was a significant disappointment for all involved. That being said, much was learned from these trials, and the knowledge gained will help to inform future research efforts.

This cannot deter us in our mission. We must now redouble our efforts as a community to stimulate new approaches to gene therapy and also cast the net wider to explore options in optogenetics, stem cell therapy, RNA therapy, and other adjunctive or preservative therapies to find treatment options and a cure for CHM.

Towards this goal, we have three items of good news. In the Fall of 2021, CRF officially launched the International Choroideremia Research Network (ICRN). This alliance of vision professionals now consists of over 90 clinicians and researchers from 25 countries. These key medical experts have joined the ICRN with the joint goal to accelerate scientific knowledge of CHM by collaborating on choroideremia research projects. To date, the group has held six virtual meetings, and established four working groups to focus on specific areas of interest within CHM research. More information and details on the ICRN can be found within this publication.

Additionally, I wanted to acknowledge the Porter and Boone families that have made an incredibly generous gift of $250,000 during our 2020-21 fiscal year to establish The Peter G. Boone Fund. This gift is one of the largest single donations ever received by CRF and will be restricted in purpose to create our first-ever endowment fund to support CHM research. We are grateful beyond words and look forward to the impact this investment will have on the future of CHM.

Finally, I wanted to thank our many volunteers, fundraisers and donors that have continued to support CRF over the past 20+ months throughout the global pandemic. This was definitely not a year of “business as usual” and we appreciate everyone who rose up above and beyond to give of their time and resources to help us continue our urgent mission. YOU are what makes CRF a FAMILY, and we could not have done it without you!

Kathi Wagner, Executive Director
The Research Committee of the Choroideremia Research Foundation organizes the scientific activity of the Foundation. The goal of the committee is to support the Foundation’s mission of finding a treatment or cure for Choroideremia and hereditary retinal-degenerative disease that causes blindness. Over the past year the Research Committee has continued to pursue its goal through a multifaceted approach. These facets include: research, discovery, and application.

Research is action. It is the process whereby theories are developed and then tested. In 2021, the Research Committee evaluated a number of research proposals. With the assistance of the Scientific Advisory Board, the Research Committee decided to provide funding for eight research proposals.

What is impressive about the funded projects is the wide spectrum that they represent. For example, five of these studies will be performed inside a laboratory, two will be conducted on actual patients, and one is the development of an animal model. Three of the projects will be conducted in Europe, and the others in North America. We remain committed to maintaining relationships with established investigators while trying to cultivate investigators that are new to us or new to the CHM space.

Discovery is the result of research. While research is the process, discovery is the product. One of our accomplishments of 2021 was to be more engaged with our funded investigators as they enter the discovery phase of their research projects. To that end, this year we were more stringent with the grant application process. This often meant having the investigator clarify certain aspects of the research proposal such as study design, statistical analysis, and the like. The product of this increased rigor was an elevation in the quality of the grants we are reviewing and approving for funding. For those investigators to whom we have provided funding, this year we have been...
more consistent about obtaining interim reports as to the progress of the project. The objective is to have projects that provide a foundation for future projects.

Research and discovery are meaningless unless they are applied. This year the Research Committee has worked on ways to accelerate the application of research discoveries. We are thinking of new and innovative ways to catalyze relationships amongst investigators of both academia and industry alike. The crowning jewel of these efforts was the creation of the International Choroideremia Research Network (ICRN). This global consortium of multidisciplinary researchers will have almost real-time access to research discoveries from literally all parts of Earth. It is hoped that members of the ICRN will be more equipped to apply these discoveries to the people they care for and for the research projects they aim to pursue. Ultimately, they will make discoveries of their own, and in turn share them with the ICRN.

2021 has been an extremely productive year for the Research Committee. So many individuals have selflessly given of their time and extensive expertise. Even more have been generous with their contributions, which is the lifeblood of research. I give thanks for all these wonderful individuals. Together we will find a cure.

Jess Thompson, MD, Research Committee Chair
2020-2021 Research Funding

Since the inception of the Choroideremia Research Foundation in 2000, the organization has provided nearly $4.5 million in research grants to find treatment options and a cure for CHM.

Recent grants have included:

**Researcher:** Mariya Moosajee, MBBS, BSc (Hons), PhD, FRCOphth, Consultant Ophthalmic Surgeon and Clinical Academic Ophthalmologist

**Institution:** University College, London, UK

SALOIS FAMILY RESEARCH AWARD: Neuroprotection for Choroideremia – funded in partnership with the Choroideremia Research Foundation Canada

**Researcher:** Vasiliki Kalatzis, PhD, Human Genetics, HDR Life Sciences

**Institution:** Institute for Neurosciences of Montpellier, INSERM, France

GLEASON FAMILY RESEARCH AWARD: A Novel Approach to Unravelling the Pathophysiology of CHM using iPSC-derived RPE from Patients- funded in partnership with the Choroideremia Research Foundation Canada
**Researcher:** David Gamm, MD, PhD, Director, McPherson Eye Research Institute; Associate Professor, Ophthalmology and Visual Sciences

**Institution:** University of Wisconsin, McPherson Eye Research Institute, Madison, WI

**THE AUBURN THETA CHI, CHI CHAPTER RESEARCH AWARD:** Generation of Human iPSc Lines with Patient-Relevant REP-1 Mutation

---

**Researcher:** Ivan Conte, PhD, Assistant Professor, Department of Biology, Polytechnic and Basic Sciences School

**Institution:** University of Naples Federico II, Italy

Pharmacological induction of autophagy to treat CHM – funded in partnership with the Penn Orphan Disease Center

---

**Researcher:** Jasleen Kaur Jolly MSc BSc (Hons) MCOptom, Senior Clinical Research Fellow

**Institution:** University of Oxford, Nuffield Department of Clinical Neurosciences, UK

**RICKETTS FAMILY RESEARCH AWARD:** The Visual Brain in the Presence of Visual Field Loss due to Genetic Eye Disease including Choroideremia (CHM)

---

**Researcher:** Cynthia Qian, MD, FRCSC, DABO, Clinical Assistant Professor

**Institution:** University of Montreal, Canada

**RANDY WHEELOCK RESEARCH AWARD WINNER:** Characterizing the phenotypical findings in female carriers with confirmed CHM mutation using multimodal imaging and functional testing; funded in partnership with the Choroideremia Research Foundation Canada
Researcher: Abigail Fahim, MD, PhD, Clinical Assistant Professor, Ophthalmology and Visual Sciences

Institution: Kellogg Eye Center, University of Michigan, Ann Arbor, MI

Investigating Choroideremia Pathophysiology using iPSC-derived Retinal Pigment Epithelium – year 2 – funded in partnership with the Choroideremia Research Foundation Canada

Researcher: Bhanu P. Telugu, DVM, PhD, President & CSO

Institution: RenOVate Biosciences, Inc.

CHM Porcine Animal Model Development – funded in partnership with Choroideremia Research Foundation Canada

Visit curechm.org/research/#funded to view a full list of research funded to date.
Clinical Trial Updates

2021 was a challenging year for choroideremia clinical trials.

In June, Biogen announced their Phase 3 STAR study of timrepigene emparvovec (BIB111/AAV2-REP1), an investigational gene therapy for the potential treatment of choroideremia, did not meet its primary endpoints. Biogen has subsequently announced they will no longer be continuing development of BIB111 for CHM.

Spark Therapeutics has also formally concluded its Safety and Dose Escalation Study of AAV2-hCHM in Subjects with CHM (Choroideremia) Gene Mutations and has also indicated they will no longer be continuing development of their clinical trial.

On a brighter note, despite the conclusion of their partnership with Genentech/Roche, 4D Molecular Therapeutics has announced they are planning to continue their Dose Escalation Study of Intravitreal 4D-110 in Patients with Choroideremia.

CRF continues to conduct outreach to industry companies engaged in related research to encourage them to expand or include CHM as an indication for future clinical trials in their development pipelines.
International Choroideremia Research Network (ICRN)

In the Fall 2021, CRF launched the International Choroideremia Research Network (ICRN), a global collaboration of clinicians and researchers from renowned institutions who are working in concert to improve scientific knowledge about choroideremia.

The network is composed of highly talented individuals from a spectrum of disciplines, perspectives, and research methods who share a passion to make significant research advances to improve outcomes for patients with choroideremia. To date, 90+ researchers from 25 countries have joined the alliance and four working groups have been established to focus on:

- Preclinical/Clinical Trials
- Pathophysiology
- Female Carriers
- International Data Collection

For more information visit www.curechm.org/icrn
CRF International Choroideremia Research Network (ICRN) Members

Members as of 12/31/2021

Alessandro Arrigo, MD, Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute, Milan, Italy

John Ash, PhD, Francis M. Bullard Eminent Scholar Chair in Ophthalmic Sciences; Associate Professor of Ophthalmology, University of Florida, United States

Carmen Ayuso, MD, PhD, Group Leader, Genetic Services, CIBER-ER, Department of Genomics, Spain

Brian Ballios, MD, PhD, FRCSC, Assistant Professor of Ophthalmology, University of Toronto, Canada

Francesco Bandello, Professor and Chairman; Department of Ophthalmology, University Vita-Salute, Italy

Mayank Bansal, MD, FRCS(Glasg), Vitreo-Retinal Surgeon, Council for Scientific and Industrial Research (CSIR) Institute of Genomics and Integrative Biology (IGIB), India

Maurizio Battaglia Parodi, Prof, Consultant, Ophthalmology Department, University Vita-Salute Scientific Institute San Raffaele, Italy

Imran Bhutto, MD, PhD, Experimental Pathologist, Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, MD

Alexander Bialasiewicz, MBA, Head, Department of Ophthalmology, Al Ahli Hospital, Doha, Qatar

David Birch, PhD, Scientific Director, Retina Foundation of the Southwest, Dallas, TX

Camiel J.F. Boon, MD, PhD, FEBO, Professor of Ophthalmology, Leiden University Medical Center, Netherlands

Maria Valeria Canto-Soler, MD, PhD, Director, CellSight – Ocular Stem Cell and Regeneration Research Program, University of Colorado School of Medicine, United States

Jenina Capasso, Director, Ocular Genetics Program, Flau Eye Institute, University of Rochester, United States

Dong Feng Chen, MD, PhD, Associate Scientist and Associate Professor of Ophthalmology at Harvard Medical School, Schepens Eye Research Institute, Harvard, MA

Ivan Conte, PhD, Assistant Professor, Department of Biology, Polytechnic and Basic Sciences School, Telethon Institute of Genetics and Medicine, Italy

Mariana Matoli da Palma, MD, Ophthalmologist, Universidade Federal de São Paulo, Brazil

Avril Daly, CEO, Retina International, Switzerland

John De Roach, BSc (Hons), PhD, Adjunct Associate Professor, University of Western Australia, Australia

Adam Dubis, PhD, Associate Professor, Institute of Ophthalmology, Faculty of Brain Sciences, NIHR Biomedical Research Centre at Moorfields Eye Hospital NHS Trust, UCL Institute of Ophthalmology, Great Britain

Mala Dutta, PhD, Technology Development Coordinator, National Eye Institute/National Institutes of Health, United States

Kim Edwards, Graduate Research Assistant, Cellular and Molecular Pathology, University of Wisconsin, WI

Malia Michelle Edwards, PhD, Assistant Professor of Ophthalmology, Wilmer Eye Institute, Johns Hopkins Medicine, Baltimore, MD

Eduardo Jover Fernandez, MD, Professor of Cellular Biology, Chairman of the Department of Histology and Anatomy, NanoBioCel/Miguel Hernandez University, Elche, Spain

David Gamm, MD, PhD, Professor, Department of Ophthalmology and Visual Sciences, University of Wisconsin, WI

Michael Gorin, MD, PhD, Chair in Ophthalmology, Chief of Retinal Disorders/Ophthalmic Genetics Division, Department of Ophthalmology, David Geffen School of Medicine, Jules St, University of California Los Angeles, United States

Ninet Z. Gregori, MD, Professor of Clinical Ophthalmology, Vitreoretinal Diseases and Surgery, Bascom Palmer Eye Institute, University of Miami, FL

Sandeepr Grover, MD, Associate Professor in Ophthalmology; Associate Chair, Department of Ophthalmology, University of Florida Health, United States

Monika Grudzinska Pechhacker, MD, PhD, FEBO, Ophthalmologist, Ocular Genetics and Clinical Visual Electrophysiology, Karolinska Institutet Sweden, Sweden

Ahmet Hondur, MD, Associate Professor in Ophthalmology, Columbia University, Ankara, Turkey

Nan Wu Hultgren, PhD, Postdoctoral Scholar, Williams Lab, Ophthalmology, UCLA, Los Angeles, CA

Jasleen Kaur Jolly, DPhil, Associate Professor in Vision and Eye Research, Vision and Eye Research Institute (VERI) School of Medicine, Anglia Ruskin University, Great Britain

Vitaly Kadyshev, PhD, MD, Senior Researcher (Laboratory of Genetic Epidemiology), Research Centre for Medical Genetics, Russia

Vasiliki Kalatzis, PhD, Human Genetics, HDR Life Sciences, French National Institute of Health (Inserm), France

Breandan Kennedy, PhD, Principal Investigator, Biomolecular & Biomedical Science, UCD Conway Institute, University College Dublin, Ireland

Anadi Khatri K C, MD, Head of Department, Birat Eye Hospital, Biratnagar, Nepal

Alam Kimura, MD, MPH, President of Denver Medical Society, Colorado Retina Associates, United States

Stephen Lam, Department of Clinical Genetics Service, Hong Kong Sanatorium and Hospital, Hong Kong

Byron Lam, MD, Professor of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, United States
Bo Lei, PhD, MD, FARVO, Chongqing Key Laboratory of Ophthalmology, Chongqing Eye Institute, First Affiliated Hospital of Chongqing Medical University, China
Alex V. Levin, MD, MHSc, Chief, Pediatric Ophthalmology and Ocular Genetics, Flaum Eye Institute, Golisano Children’s Hospital, Rochester, NY
Richard Alan Lewis, MD, MS, Professor of Molecular and Human Genetics, Ophthalmology, and Medicine, Baylor College of Medicine, Houston, TX
Sandra Liakopoulos, MD, Ophthalmologist, University Hospital Cologne, Germany
Moritz Lindner, MD, Institute for Physiology and Pathophysiology, Philipps University, Marburg, Germany
Tein Luu, BS, Research Assistant, Retina Foundation of the Southwest, Dallas, TX
Ian MacDonald, MD, CM, Professor Emeritus in the Department of Ophthalmology and Visual Sciences, University of Alberta Canada, Edmonton, Canada
João Pedro Marques, MD, MSc, FEBO, Ophthalmologist, Centro Hospitalar e Universitario de Coimbra EPE, Portugal
Nathalie Massamba, MD, Department of Ophthalmology, Moran Eye Center, University of Utah, United States
Tracy Matchinski, OD, FAAO, Associate Professor of Optometry, Coordinator, Low Vision Rehabilitative Services, Illinois College of Optometry, United States
Christelle Monville, PhD, Researcher at ISTEM, Institute for Stem Cell Therapy and Exploration of Monogenic Diseases (ISTEM), France
Mariya Moosajee, MBBS PhD FRCoph, Professor of Molecular Ophthalmology, University College, London, Great Britain
Ala Moshiri, MD, PhD, Associate Professor, Department of Ophthalmology, UC Davis Health, CA
Rebecca Nelson, Inherited Retinal Disease Service Coordinator, Colorado Retina Associates
Oscar Muwale Onyango, MB, ChB, MMed, Ophthalmologist, Nairobi Eye Associates Limited, Kenya
Serdar Oruc, Department of Neurology, Acibadem University, Turkey
Fernanda Belga Ottoni Porto, MD, PhD, Ophthalmologist, INRET Clinica e Centro de Pesquisa, Belo Horizonte, Brazil
Supraja Prakash, MS, CGC, Counselor at Phoenix Children’s Hospital, Phoenix Children’s Hospital, United States
Markus Preising, PhD, Department of Ophthalmology, Faculty Member, Justus-Liebig-University Giessen, Germany
Cynthia Xin Ya Qian, MD, FRCSC, DABO, Vitreoretinal Surgery, University of Montreal, Quebec, Canada
Richard Rosen, MD, Ophthalmologist, New York Eye & Ear Infirmary of Mount Sinai, United States
Jose Maria Ruiz-Moreno, MD, PhD, Ophthalmologist, Vissum Alicante, Spain
Juliana Maria Ferraz Sallum, MD, PhD, Affiliate Professor, Federal University of São Paolo, Brazil
Dror Sharon, PhD, Sharon Laboratory Head, Hadassah Medical Group, Jerusalem, Israel
Julie Silvestri, MD, FRCP, FRCOphth, Leading Eye Consultant, Belfast Health and Social Care Trust, Ireland
Matthew Simunovic, MB, BCHir, PhD, Eye Surgeon and Retinal Specialist, Sydney Eye Hospital, Australia
Divya Sinha, PhD, Assistant Scientist, Waisman Center, University of Wisconsin, United States
Malie Solano, Clinical Research Supervisor, Colorado Retina Associates
David Sousa, MD, PhD, Ophthalmologist/Eye Surgeon, Royal Victorian Eye & Ear Hospital, Melbourne, Australia
Janet Sparrow, PhD, Professor of Ophthalmic Science (in Ophthalmology), Professor of Pathology & Cell Biology, Columbia University Medical Center, United States
Katarina Stingl, MD, Center for Ophthalmology, University Eye Hospital, Germany
Anand Swaroop, PhD, Neurobiologist, Neurodegeneration & Repair Laboratory, National Eye Institute, National Institute of Health, United States
Zurriat Syed, BA, MS, D.O. Candidate 2024, LMU-DeBusk College of Osteopathic Medicine, United States
Silvia Sörensen, PhD, Associate Professor Counseling & Human Development, Warner School of Education and Human Development, University of Rochester, United States
Adda Villanueva, MD, Clinician, MejoraVisionMD, Merida, Yucatan, Mexico
David Williams, PhD, Professor In-Residence, Ophthalmology, University of California, Los Angeles, CA
Se Joon Woo, MD, PhD, Associate Professor, Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, South Korea
Manlong Xu, MD, PhD, Clinical Research Fellow, University of Alberta, Edmonton, Canada
Kanmin Xue, PhD, FRCophth, Wellcome Trust Clinician Scientist Fellow, Oxford University, Nuffield Department of Clinical Neurosciences, Oxford, United Kingdom
Fay Zhai, MD, PhD, Clinical Research Fellow, University of Alberta, Edmonton, Canada
Dinah Zur, MD, Ophthalmology Division and Retina Specialist, Tel Aviv Sourasky Medical Center, IL

2021 Annual Report
International Advocacy Efforts

During 2021, CRF engaged with medical professionals, regulators, nonprofit allies, and the rare disease community-at-large at various convenings.

International advocacy and outreach efforts to medical professionals included attending in-person gatherings of the August International Society for Genetic Eye Disorders and Retinoblastoma (ISGEDR) in Switzerland, presenting at Denmark’s annual meeting of Dansk Blindesamfund, exhibiting and presenting at the November American Academy of Optometry (AA-Opt) Annual Meeting in Boston, and attending the American Academy of Ophthalmology (AAO) Annual Meeting in New Orleans. Virtual event participation included attending Global Genes, the American Society of Human Genetics, Rare Disease Week, the American Society of Gene and Cell Therapy (ASGCT), the Association for Research and Vision in Ophthalmology (ARVO), and more.
CRF regulatory advocacy this year included participation in virtual meetings of the Food and Drug Administration (FDA), the National Institutes of Health (NIH), the National Center for Advancing Translational Science (NCATS), the National Eye Institute (NEI), and the Center for Biologics Evaluation and Research (CBER).

CRF also has continued ongoing collaborative participation with the Rare and Ultra Rare disease communities via Global Genes, the National Organization for Rare Disorders (NORD), EURORDIS, and the Haystack Project.

Genetic testing remains an advocacy priority through our participation in the UK Eye Genetics Group, US Ophthalmic Genetics Study Club, and the International Society of Gene and Cell Therapy (ISGCT). This effort has led CRF to be an invited presenter for a 2022 genetic counselors meeting which will provide continuing medical education credits. The CRF has also joined Retina International’s new task force for Global Genetic Testing Access, which will begin in 2022.

One of the best examples of CRF Rare Disease advocacy is our foundation’s new initiative to centralize the incredibly valuable CHM patient natural history data which has been collected from across the globe to help advance future CHM research. The CRF has been collaborating with the Critical Path Institute’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®), which is an FDA-funded initiative. This is a long-term effort to consolidate this data in a well-protected and administered database. It is anticipated that the first large CHM data group will be made available in the latter part of 2022 initiating participation in this program.
**Patient and Family Services**

**PROGRAM HIGHLIGHTS**

- 12 new “Meet A CHM Family Member” videos and other video interviews
- 12 new webinars
- 35,799 CRF website page views from 21,754 unique users
- CHM Eye Donation Program launched in May 2021
- 12,691 people served in 2021

**HOUSEDHOLD MEMBERSHIPS**

- Free Memberships 209
  Free Members 326
- Annual Memberships 53
  Annual Members 91
- Lifetime Memberships 188
  Lifetime Members 335
- Total Memberships: 450 (375 last year)
- Total Members: 752 (693 last year)

---

**44 VIRTUAL**

social/support events

---

**2,100**

Facebook Followers

---

**25,000+ VIEWS**

to date of 125+ videos on our YouTube channel

---

**Other Accomplishments**

- 2021 Great Non-Profits “Top Rated” Charity status
- Highest Platinum Rating from charity watchdog group Candid/Guidestar
- 100 of 100 score from Charity Navigator – “Give with Confidence”
CHM Family Accomplishments

CHMer Sam Harding finished as a finalist in the T12/13 1500m run in the 2021 Tokyo Paralympics!

Isaac Thompson (son of CRF Science Advisory Board Chair Dr. Jess Thompson) and Max Moen (son of CRF Chief Medical Officer and Board Member Dr. Chris Moen) proudly competed and represented Team CHM in the 2021 Toyota USA Triathlon National Championships in Milwaukee, WI.

Brian Counter created a 24 hour Gaming Marathon Fundraiser for CRF!

We are grateful to Jon Salois who raised over $3,000 and ran 26.2 miles in a 2020 Virtual Marathon!
The Holbrook Family Virtual Event Raised nearly $22,600.

We are grateful to the Kazmierczak Family for hosting a Yard Sale to benefit CRF!

Million Dollar Bike Ride 2021 - Team CHM raised over $34,000 and exceeded the $30,000 match goal from the Penn Orphan Disease Center!

“I’m Damon Holbrook, and I am a sophomore at Park City High School. My little brother and I, my grandpa, and multiple cousins have CHM...I’m trying to raise money for this organization because I don’t want me or anyone else in my family to go blind. We know that there is hope for a cure in the near future. We are excited to do this fundraiser and appreciate all of your support. “

Congratulations to Tommy Miller who participated in an Ironman “70.3 Eagleman” to raise awareness and funds for choroidermia research and education!
Shout out to the brothers of Theta Chi at Auburn University who raised $20,000 to benefit CRF with a car wash, silent auction and Dining in the Dark event.

The Laudenbach family raised over $5,700 at their annual Run for a Reason to benefit CRF!

Thanks to our 48 Facebook fundraisers!

2021 TCS New York Marathon - Team CRF

30 runners signed up to represent TEAM CHM in the TCS New York City Marathon and raised over $94,000 to benefit CRF!
### Financial Summary

#### Fiscal Year Financials

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unrestricted Revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Donations</td>
<td>$385,651</td>
<td>$538,010</td>
</tr>
<tr>
<td>Investment Income</td>
<td>$329</td>
<td>$16,228</td>
</tr>
<tr>
<td>Other Income</td>
<td>36,393</td>
<td>0</td>
</tr>
<tr>
<td><strong>Unrestricted Revenue Subtotal</strong></td>
<td><strong>$422,373</strong></td>
<td><strong>$554,238</strong></td>
</tr>
<tr>
<td>Restricted Revenue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Peter G. Boone Endowment Fund</td>
<td>$250,000</td>
<td></td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>$672,373</strong></td>
<td><strong>$554,238</strong></td>
</tr>
<tr>
<td><strong>Expenses</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Program Activities</td>
<td>$133,553</td>
<td>$162,909</td>
</tr>
<tr>
<td>Research Funding</td>
<td>$322,259</td>
<td>$363,991</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$67,303</td>
<td>$60,937</td>
</tr>
<tr>
<td>Management</td>
<td>$50,934</td>
<td>$53,092</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>$574,049</strong></td>
<td><strong>$640,929</strong></td>
</tr>
<tr>
<td><strong>End of Year, Unrestricted (Operating) Assets</strong></td>
<td><strong>$655,807</strong></td>
<td><strong>$807,483</strong></td>
</tr>
<tr>
<td><strong>End of Year, Restricted Assets</strong></td>
<td><strong>$250,000</strong></td>
<td><strong>$0</strong></td>
</tr>
<tr>
<td><strong>Total Net Assets</strong></td>
<td><strong>$905,807</strong></td>
<td><strong>$807,483</strong></td>
</tr>
</tbody>
</table>

(July 1 - June 30)
2021-22 Board of Directors

Neal Bench
President
Chapel Hill
North Carolina

John Trott
1st Vice President
Westfield
New Jersey

Michael Mullen
2nd Vice President
Carmel
Indiana

Kayla Schiller
Treasurer
Claflin
Kansas

Brian Mayer
Secretary
Brookfield
Illinois

Officers At Large

Chris Moen, MD
Wilmington
Delaware

Tara Cassidy-Driscoll
Swampscott
Massachusetts

Stephanie Sims, MD
Jacksonville
Florida
Directors

Naama Goldman, PhD
Tel Aviv
Israel

Bob Hillier
Ontario
Canada

Michael Langsfeld
Friedberg/Hessen
Germany

Jason McKinney
Gilmer
Texas

John Oster
Rochester
New York

Dan Peterson
Trimont
Minnesota

Tracey Pretorius
Kirkland
Washington

Angela Ricketts
St. Louis
Missouri

John-Ross Rizzo, MD
New York
New York

Craig Rowley
Jay
Maine

Jon Salois
Worcester
Massachusetts
2021-22 Scientific Advisory Board

Jess Thompson, MD, MS, Chair
Chair, Research Committee, Choroideremia Research Foundation
Cardiothoracic Surgeon, Yavapai Cardiac Surgery
Prescott, Arizona

Tomas Aleman, MD
Associate Professor of Ophthalmology at the Hospital of the University of Pennsylvania, Perelman School of Medicine
University of Pennsylvania Philadelphia, Pennsylvania

Kapil Bharti, PhD
Senior Investigator, Ocular and Stem Cell Translational Research Unit, National Institutes of Health, Intramural Research Program
Bethesda, Massachusetts

Jacque Duncan, MD
Professor in Ophthalmology, University of California San Francisco
San Francisco, California
Rachel Huckfeldt, MD, PhD
Associate Surgeon and Director, Inherited Retinal Degenerations Fellowship, Massachusetts Eye and Ear; Assistant Professor of Ophthalmology, Harvard Medical School
Boston, Massachusetts

Alex Iannaccone, MD, MS, FARVO
Director, Center for Retinal Degenerations and Ophthalmic Genetic Diseases, and Professor, Ophthalmology, Duke University Department of Ophthalmology
Durham, North Carolina

Maureen McCall, PhD
Professor & Vice Chair for Research, Department of Ophthalmology & Visual Sciences, School of Medicine, University of Louisville
Louisville, Kentucky

Mark Pennesi, MD, PhD
Assistant Professor in Ophthalmic Genetics, Oregon Health and Science University (OHSU) Casey Eye Institute
Portland, Oregon

Stephen Tsang, MD, PhD
Professor of Ophthalmology and Professor of Pathology and Cell Biology, Columbia University Department of Pathology and Cell Biology
New York, New York

Ajoy Vincent, MBBS, MS
Staff Ophthalmologist, Ophthalmology and Vision Sciences; Medical Director, Visual Electrophysiology Unit; Associate Scientist Genetics and Genome Biology Research Institute, The Hospital for Sick Children
Toronto, Ontario, Canada
Michael Young, PhD, FARVO
Associate Professor of Ophthalmology, Co-Director, Ocular Regenerative Medicine Institute; Director, Minda de Gunzburg Center for Retinal Regeneration, Harvard Medical School; Associate Scientist, Schepens Eye Research Institute of Massachusetts Eye and Ear
Boston, Massachusetts

Chris Moen, MD
Chief Medical Officer, Choroideremia Research Foundation Medical Director, NaviHealth
Wilmington, Delaware

Staff

Full-Time

Kathi Wagner
Executive Director

Part-Time

Beth Foss
Operations

Eric Hartman
Patient Advocacy

Cory MacDonald
Patient Engagement

Reagan Devinney
Social Media and Marketing
## Donors

### $10,000+
- Biogen
- Yair Einhorn and Naama Goldman
- Hugh and Nancy Hutchison
- Mary Porter
- Spark Therapeutics, Inc.

### $5,000-9,999
- Michael and Michelle Holbrook
- John and Loron Oster
- Chad and Jennifer Rakvin
- Yamil Rosete Rodriguez
- Joe and Joanne Salois
- Santen Pharmaceutical
- Within Sight Foundation

### $2,500-4,999
- Atlas Distributing, Inc.
- Jeff and Julie Benelli
- Ed Lucas Foundation
- Kevin and Dawn McCarthy
- Microsoft Gift Match
- John and Sandy Polkowski
- Tracey Pretorius
- Matthew and Angela Ricketts
- The Parkes Companies, Inc.
- Jeff Warner

### $1,000-2,499
- Anonymous
- Bank Of America Foundation
- William and Barbara Barr
- William Bauer
- Roland and Margrit Bechade
- Neal and Jeanette Bench
- Tyler Bench
- Stephanie Benson
- Glyn and Betsy Boone
- Josh Brose
- Craig and Ellen Brown
- Keith and Barb Cameron
- Daniel Connolly
- Cornell Dubilier Electronics, Inc.
- Jeani Cunningham
- Peter Dalrymple
- Dan Daul
- Jenny Doering
- William Seymour and Rosemary Driscoll
- Edwards Lifesciences Foundation
- John and Barbara Fenner
- Fidelity Charitable
- Jason Folie
- GE Foundation
- Ann Gillespie
- Charles Gleason and Maryanne Driscoll
- Richard and Constance Guerin
- John Guyon
- Kelly Halder
- Sean and Sharalyn Hoffman
- Richard and Pam Holley
- Illinois Tool Works
- William and Caroline Looney
- Cory and Karen MacDonald
- Christopher and Alisa Moen
- Michael Mullen
- Bernard and Shari Nutter
- Joseph and Laura Ogg
- Sarah Pennington
- Bob and Paige Pettipaw
- Steven and Elizabeth Reiling
- Marty and Marilyn Reiss
- Ross Rizzo
- Ira and Erica Robbins
- Earl and Ellen Russell
Kayla Schiller
David Stateman and Sondra Hoffman
Suzanne Sullivan
Jess and Sarah Thompson
Vrishali Thorat
Town Fair Tire Founation
John and Dominique Trott

$500-999
Monique Alexander
Bryan Baugh
Maria Bautista and Heidi Brown
Brandon Becker
Bruce and Jane Bench
Gloria Calhoun
Marilyn Cassidy
Tom Driscoll and Tara Cassidy-Driscoll
Michael and Patricia Cavanagh
James Coghlin
Mitch and Nancy Cubrich
Omer Einhorn
Robert and Beth Foss
Franke Family Charitable Fund
Flora Fung
Joseph and Brenda Garrison
Lawrence and Wynette Hall
Robert and Bettye Halperin
Edward Hoffman
Janet Jakobe-Gray
Scott Janczyk and Hilary Habib
Paul Janczyk
Mary Jewell
Douglas and Kathryn Jones
Michael and Gail Kane
Agnes Kane
Maureen Kavjian
Tim and Sue Kazmierczak
Simon Keymer
Rachel Kimball
Christopher Lane
Jean-Pierre and Catherine Lanteri
Dan Levy
Bonita Linn
Marathon Petroleum Company
Brian Mayer
Mark McClure
Michael and Shawna McDonald
Sean and Jodi McLaughlin
Ronald McLeroy
Glen and Kathryn Miller
Ann Nally
Charles and Patricia Oster
Kyra Padula
Keith and Kristy Payne
Maartin and Ruth Pereboom
Dan Peterson
Steve Pettipaw
Bernice Pettit
Harirahan Ravi
Donald and Louise Richards
Robert Ritchie
Andrea Roueche
Joe and Cathy Salois
David and Patricia Schmidt
Ed and Marion Scott
Vivian Spates
Richard Speidel
Frances Stanfield
Teresa Tatton
David and Krista Thomas
John and Stephanie Tiedemann
Mikael Törmänen
Martin and Sue Ulshen
Kevin Walker
William Wilson and Jennifer Maude
Ian and Coralie Witter
Menglan Xiang

$250-$499
Erland and Gloria Anderson
Joel Anderson
Wayne and Mary Andrus
Sylvia Bediamol
Scott Besser
Nicole Blondin
Marielle Boily
Mark Breinholt
Jesse Brennan
Jane Brown
Danielle Campbell
Chubb Charitable Foundation
Nicholas Cole
Colleen Comeau
Kathleen Counter
Spencer Crawford
Ann Marie Dike
Bryan Doherty
Ruth Edwards
Amit Einhorn
Yona Erblat
Alexandra Fleischman
Crystal Flick
Jeremy and Patricia Gelbwaks
Albert and Kristen Ging
Graphic Purchasing Solutions, LLC
Joe and Diane Gullo
Jeffrey Guy
Olivier Harel
H. Eric Hartman
Holly Haslam
Pamela Hemminger
Kurt Hirsch
John Hirshberger
IBM Employee Service Center
Josephine Ingram
Evelyn Jolin
Baird Kellogg
Charles Kurose
John and Janet Laudenbach
Robert and Linda Lund
Marathon Oil
Heidi Mayer
Scott and Barbara McFadden
Michael Merz
David and Maria Moen
Michael and Kimberly Monahan
Emily Moseley
Nordson
Kevin and Maureen O’Beirne
Lisa Olson
Indu Parikh
Robert and Mary Pettipaw
Scott Petts
Vincent Porreca
John Powell
Paul Pritchard
Rollie and Sandra Purvis
Jan and Lori Rische
Diane Rumpel
Jonathan Salois
Jamie Salois
Charlie and Julia San Fratello
Sharlene Sandow
Brook and Deb Schroeder
Matthew Schultz
Bob and Jean Scott
Denise Sims
Justin and Stephanie Sims
Sarah Smith
Helen Smith
Trailblazers
Dean and Trena Trowhill
Daniel Vos
Stefan Vraspir
Kristin Vujanovic
Joseph and Kathi Wagner
Leslie Ward
Scott and Karen White
Margie Willis
John and Susan Wilson
Christin Zindrick

$100-$249
Jordan Abercrombie
Ryan Anson
Diane Asay
Jessica Azzi-Saliba
Kimberly Ballman
Bob Beasley
Robert Becker
Jamezetta Bedford
Fred Bell
Judy Benson
Harriet Berard
Kathleen Betz
Howard Black
Denise Bonemeyer
Gary Boulton
Duygu Bozkaya
Michael and Barbara Brady
Darren and Amanda Braml
Christ Braun
Annie Brayboy
Stephen and Carol Brennan
Bright Funds
Delilah Brown
Sharon Bushnell
Alejandro Cadena
Nancy Calhoun
Dan Calhoun
Heather Callister
Kathy Cameron-Kuehn
Chris Campbell
With a planned gift to the Choroideremia Research Foundation, you can combine your desire to give to charity with your overall financial, tax, and estate planning goals.

Planned giving gives you a special connection with CRF. You will help those affected by choroideremia—for now and for years to come. For more information, please contact Kathi Wagner, Executive Director, at 800-210-0233 x 5 or kathiwagner@curechm.org.
Harry Jon and Maria Saxen
John Scarimbolo
Petra Schaefer
Andrea Schiller
Parker Schlink
Jim and Barbara Schroeder
Jon Schwartz
Hubert Seymour
Mike Sharkey
Harsh Sharma
Julie Simondet
Jonathan Skinner
Julie Smith
Elizabeth Smith
Renuka Soll
Nick Springmann
Robert and Jennifer Staley
Lori Stanfa-Schroeder
Patricia Stelz
Thomas Stevenson
BJ Stinger
Matthew and Kristine Stock
Janet Stosur
Nancy Strauss
Joseph Stumpf
Laura Swint
Paulette Talbot
William Tan
Calvin and Carol Thomas
Thrivent Financial
Susan Tibbetts
Joycelyn Tinsley
Daniel Ulshen
Steve Varughese
Ben and Maria Veach
Kris Verich-Dungan
Anthony and Daniele Vetere
Connie Vignes
Fredvelia E. Virella
Carolyn Vitale
Graham Walker
Gary Ward
Joanna Watson
Carl and Cathy Wegener
Linda Weisel
Michael Zawacki
Xilong Zhao
Scott Zink
Ann Zurn

Every effort has been made to recognize each donor correctly. We apologize for any omissions or errors. If we need to make corrections to your listing, please call us at 800-210-0233, ext. 1 or email us at info@curechm.org.